natgillin/translations-raw huggingface dataset:
Spironolactone and its active metabolites (including 7α-thiomethyl-spironolactone and canrenone) act as specific antagonists of aldosterone, and exert their effects by binding competitively to the mineralocorticoid receptor located in the kidneys, heart and blood vessels.
Spironolakton i njegovi aktivni metaboliti (uključujući 7α – tiometil - spironolakton i kanrenon) djeluju kao specifičnih antagonisti aldosterona, vežući se kompetitivno na mineralokortikoidne receptore koji se nalaze u bubrezima, srcu i krvnim žilama.
Spironolactone Ceva 10 mg tablets for dogs Spironolactone Ceva 40 mg tablets for dogs Spironolactone Ceva 80 mg tablets for dogs Spironolactone.
Spironolactone Ceva 10 mg tablete za pse Spironolactone Ceva 40 mg tablete za pse Spironolactone Ceva 80 mg tablete za pse
Spironolactone Ceva tablets are used in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.
Za primjenu pri standardnoj terapiji (uključujući po potrebi diuretike) kod kongestivnog zatajenja srca u pasa, uzrokovanog valvularnom regurgitacijom.
Spironolactone is rapidly and completely metabolised by the liver into its active metabolites, 7α- thiomethyl-spironolactone and canrenone, which are the primary metabolites in the dog.
Spirinolakton se brzo i u potpunosti metabolizira u jetri u svoje aktivne metabolite, 7α – tiometil - spironolakton i kanrenon, koji su primarni metaboliti u pasa.
Spironolactone is rapidly and completely metabolised by the liver into its active metabolites, 7α- thiomethyl-spironolactone and canrenone, which are the primary metabolites in the dog.
Spironolakton se ubrzano i potpuno metabolizira putem jetre u svoje aktivne metabolite, 7alfa- tiometil-spironolakton i kanrenon koji su glavni primarni metaboliti u pasa.
Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could affect the metabolism of other substances utilizing these metabolic pathways.
Spironolakton može uzrokovati i indukciju i inhibiciju enzima citokrom P450 te može utjecati na metabolizam drugih tvari koje koriste ove puteve metaboličke razgradnje.
Spleen size should be evaluated regularly.
Potrebno je redovito određivati veličinu slezene.
Spleen volume
Volumen slezene
Spleen Volume (MN)
Volumen slezene (MN)
Spleen1
Slezena1
Splenic adverse reactions
Nuspojave vezane uz slezenu
Splenic infarction
infarkt slezene
Splenic rupture a
ruptura slezenea
Splenic rupture Sickle cell crisisa
ruptura slezene kriza kod anemije srpastih stanicaa
Splenic rupturea
ruptura slezenea
Splenic rupturea Sickle cell crisisa
Kriza srpastih stanicaa
Splenic rupturea Sickle cell crisisa
Ruptura slezenea Kriza srpastih stanicaa
Splenic rupturea Splenomegalya, e Sickle cell crisisa
Ruptura slezenea Splenomegalijaa, e Kriza srpastih stanicaa
Splenic rupturea Thrombocytopeniaa
Ruptura slezenea
Splenic rupturea Thrombocytopeniaa
Ruptura slezenea Trombocitopenija a
Splenic rupturea Thrombocytopeniaa
Ruptura slezenea Trombocitopenijaa
Splenomegaly
plenomegalija
Splenomegaly
Splenomegalija
Splenomegaly a
plenomegalijaa
Splenomegaly Anaemia
glavobolja
Splenomegaly Anaemia
plenomegalija anemija
Splenomegaly and splenic rupture were also reported.
Također su zabilježene splenomegalija i ruptura slezene.
Splenomegaly and splenic rupture were also reported.
Zabilježene su i splenomegalija i rupture slezene.
Splenomegaly is a direct effect of treatment with filgrastim.
Splenomegalija izravna je posljedica primjene filgrastima.
Splenomegaly is a direct effect of treatment with filgrastim.
Splenomegalija je izravni učinak liječenja filgrastimom.
Splenomegaly was reported to be related to filgrastim therapy in < 3% of patients.
Splenomegalija je prijavljena kao povezana s terapijom filgrastimom u < 3 % bolesnika.
Splenomegaly was reported to be related to filgrastim therapy in < 3% of patients.
Splenomegalija povezana s liječenjem filgrastimom zabilježena je u <3% bolesnika.
Splenomegaly was reported to be related to filgrastim therapy in < 3% of patients.
Splenomegalija povezana s primjenom filgrastima prijavljena je u < 3% bolesnika.
Splenomegaly was reported to be related to filgrastim therapy in <3% of patients.
Splenomegalija povezana s liječenjem filgrastimom zabilježena je u <3% bolesnika.
Splenomegalya
plenomegalijaa
Splenomegalya
Splenomegalij aa
Splenomegalya
Splenomegalija a
Splenomegalya
Splenomegalijaa
Splenomegalya Anaemia
Splenomegalijaa Anemija
Splenomegalya, e
plenomegalijaa, e
Split influenza virus inactivated, containing antigen equivalent to:
fragmentirani virus influence,inaktiviran, koji sadrži antigen koji odgovara soju:
Split influenza virus, inactivated, containing antigen equivalent to:
Fragmentirani virus influence, inaktiviran, sadrži antigen koji odgovara soju:
Split influenza virus, inactivated, containing antigen* equivalent to
fragmentirani virus influence, inaktivirani, sadrži antigen* koji odgovara:
Split influenza virus, inactivated, containing antigen* equivalent to:
fragmentirani virus influence, inaktiviran, sadrži antigen* koji odgovara:
Split influenza virus, inactivated, containing antigen* equivalent to: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) 3.75 micrograms**
Virus influence (fragmentiran, inaktiviran), sadrži antigene* koji odgovaraju soju: A/VietNam/1194/2004 (H5N1) poput kojeg je korišten soj (NIBRG-14) 3,75 mikrograma
Split-thickness skin graft donor site wound studies (pooled)
Ispitivanja rana donorskog mjesta kožnog presatka djelomične debljine (objedinjeno)
SPMs are known to be associated with lenalidomide exposure, which was extended in patients treated with Empliciti combined with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone.
Poznato je da se druge primarne zloćudne bolesti povezuju s izlaganjem lenalidomidu, koje je bilo dugotrajnije u bolesnika liječenih lijekom Empliciti u kombinaciji s lenalidomidom i deksametazonom nego u onih liječenih lenalidomidom i deksametazonom.
spondyloarthropathy, Sjogren’s syndrome, arthritis, myopathy
spondiloartropatija, Sjögrenov sindrom, artritis, miopatija
Spontaneous abortion
pontani pobačaj
Spontaneous abortion (rate of 45-49%) and congenital malformations (estimated rate of 23-27%) have been reported following MMF exposure during pregnancy.
Nakon izlaganja mofetilmikofenolatu tijekom trudnoće prijavljeni su spontani pobačaj (stopa: 45 – 49%) i kongenitalne malformacije (procijenjena stopa: 23 – 27%).
Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil.
Spontani pobačaji prijavljeni su kod 45 – 49% trudnica izloženih mofetilmikofenolatu, u usporedbi sa stopom od 12 do 33% prijavljenom u bolesnica s presatkom solidnog organa liječenih drugim imunosupresivima osim mofetilmikofenolata.
Spontaneous bleeding from the eye, rectum, gums or in the abdomen around the internal organs
pontana krvarenja iz oka, rektuma, desni ili oko unutarnjih organa u trbuhu
Spontaneous bleeding or bruising (signs of low level of platelets, also known as thrombocytopenia)
Spontano krvarenje ili pojava modrica (znakovi niske razine krvnih pločica, također poznate kao trombocitopenija)
Spontaneous bleeding or bruising, signs of low level of platelets (thrombocytopenia)
Spontano krvarenje ili pojava modrica, znakovi niske razine krvnih pločica (trombocitopenija)
Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT.
Spontane egzacerbacije kroničnog hepatitisa B relativno su česte i karakteriziraju ih prolazno povišene razine ALT u serumu.
Spontaneous penile erection
Spontana erekcija
Spontaneous penile erection, Menstrual disorder
spontana erekcija, menstrualni poremećaji
Spoon for stirring
Žlica za miješanje
Spot-on
Spot-on otopina
Spot-on
Spot-on.
Spot-on application only.
Isključivo primijeniti na kožu.
Spot-on application only.
Otopina samo za nakapavanje na kožu.
Spot-on applicator
Aplikator za nakapavanje
Spot-on applicator (COC) with polymer cap
Spot-on aplikator (HOO) s polimerskom kapicom
Spot-on applicator (PE/Alu/PE)
Aplikator za nakapavanje (PE/Alu/PE)
Spot-on applicator label
Naljepnica aplikatora za nakapavanje
Spot-on applicator made of a multilayered complex of aluminium and polyethylene (PE) with a head made of HDPE, top-sealed with a liner complex (aluminium/polyester/sealable PE layer).
Aplikator za nakapavanje načinjen je od višeslojnog kompleksa aluminija i polietilena (PE) sa zapečaćenim poklopcem od HDPE s umetkom (aluminij/poliester/PE sloj koji se može zapečatiti).
Spot-on solution
Otopina za nakapavanje
Spot-on solution
Otopina za nakapavanje na kožu
Spot-on solution
Otopina za nakapavanje na kožu.
Spot-on solution
Otopina za nakapavanje.
Spot-on solution
Spot on otopina
Spot-on solution
Spot-on solucija
Spot-on solution for external application to the skin
Spot-on otopina za vanjsku primjenu na koži.
Spot-on solution Intervet UK Limited Walton Manor, Walton, Milton Keynes,
Otopina za nakapavanje Intervet UK Limited Walton Manor, Walton, Milton Keynes,
Spot-on solution.
Otopina za nakapavanje na kožu.
Spot-on solution.
Otopina za nakapavanje.
Spot-on solution.
Spot on-otopina.
Spot-on solution.
Spot-on otopina
Spot-on solution.
Spot-on otopina za nakapavanje na kožu.
Spot-on use
Nakapavanje
Spot-on use
Nakapavanje na kožu
Spot-on use
Nakapavanjem
Spot-on use
Nakapavanjem.
Spot-on use
Otopina za nakapavanje na kožu.
Spot-on use
Put primjene
Spot-on use
Spot on primjena.
Spot-on use
Spot-on otopina
Spot-on use
Spot-on upotreba
Spot-on use
Za nakapavanje na kožu.
Spot-on use for external application to the skin.
Spot-on otopina za vanjsku primjenu na koži.
Spot-on use for external application.
Spot-on uporaba za vanjsku primjenu.
Spot-on use.
Otopina za nakapavanje na kožu.
Spot-on use.
Spot-on
Spot-on use.
Spot-on primjena.
Spot-on use.
Za nakapavanje na kožu.
Spot-on-solution
Spot-on otopina
Spot-on-solution.
Otopina za nakapavanje.
Spray application
Primjena raspršivanjem
Spray application using Raplixa spray device followed by gelatin sponge
Primjena raspršivanjem uređajem RaplixaSpray nakon čega slijedi stavljanje želatinske spužvice
spray bottle:
Bočica sa 2 potiska:
Spray distance from tissue and CO2 pressure should be within the ranges recommended by the manufacturer (see table in Section 6.6 for pressure and distance).
Udaljenost od tkiva i tlak CO2 moraju biti unutar raspona koje preporučuje proizvođač (za tlakove i udaljenosti, vidjeti tablicu u dijelu 6.6).
Spray distance from tissue and pressure should be within the ranges recommended by the manufacturer (see table in Section Instructions for Use).
Udaljenost raspršivača od tkiva i tlak moraju biti unutar raspona koje preporučuje proizvođač raspršivača (pogledajte tablicu u dijelu Upute za uporabu).
Spray dried pork liver
Svinjska jetra osušena prskanjem
Spray method
Raspršivanje:
Spray preferably in a well ventilated area.
Prskati u dobro ventiliranom prostoru.
Spray RevitaCAM into dog’s mouth
Raspršite RevitaCAM u usta psa
Spray set to be used
Komplet za raspršivanje koji se koristi
Spray set to be used
Predviđen komplet za raspršivanje
Spray vaccination:
Cijepljenje pomoću raspršivača:
sprayer (alu)
sprej (aluminijski spremnik)
sprayer (glass) in trays
Aplikatori (stalko) na podlošcima
sprayer (glass/PE)
raspršivač (staklo/PE)
Spread of IMLYGIC to close contacts or healthcare providers after direct contact with injected lesions or body fluids
Širenje lijeka IMLYGIC na osobe u neposrednoj blizini ili zdravstvene radnike nakon izravnog kontakta s injiciranim lezijama ili tjelesnim tekućinama
Sprinkle the contents of the capsule on the food (illustration d).
Pospite sadržaj kapsule po hrani (ilustracija d).
Sprinkle the granules onto apple sauce or yogurt.
Posipajte granule izravno na kašicu od jabuke ii jogurt.
Sprinkling in orange juice or any acidic fruit juice
Prosipanje u sok od naranče ili bilo koji kiseli voćni sok
Sprinkling on food
Posipanje po hrani
SPRINT-2
SPRINT–2
SPRINT-2 (P05216) was a randomized, double blinded, placebo-controlled study comparing two therapeutic regimens of Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based dosing with ribavirin (600- 1,400 mg/day orally divided twice daily)] to PR alone in adult subjects who had chronic hepatitis C HCV genotype 1 infection with detectable levels of HCV-RNA and were not previously treated with interferon alfa therapy.
SPRINT-2 (P05216) je bilo randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje u kojem su uspoređena dva režima liječenja: Victrelis 800 mg peroralno triput na dan u kombinaciji s PR-om [peginterferonom alfa-2b supkutano u dozi od 1,5 µg/kg/tjedno i ribavirinom u dozi prilagođenoj tjelesnoj težini bolesnika (600 -1400 mg/dan peroralno, podijeljeno u dvije doze)] u usporedbi s primjenom samo PR-a u odraslih bolesnika s kroničnim hepatitisom C HCV genotipa 1 s mjerljivom razinom HCV-RNK i koji prethodno nisu bili liječeni interferonom alfa.
SPRYCEL 100 mg film-coated tablets dasatinib
SPRYCEL 100 mg filmom obložene tablete dasatinib
SPRYCEL 100 mg tablets dasatinib
SPRYCEL 100 mg tablete dasatinib
SPRYCEL 140 mg film-coated tablets dasatinib
SPRYCEL 140 mg filmom obložene tablete dasatinib
SPRYCEL 140 mg tablets dasatinib
SPRYCEL 140 mg tablete dasatinib
SPRYCEL 20 mg film-coated tablets EU/1/06/363/004
SPRYCEL 20 mg filmom obložene tablete EU/1/06/363/004
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets
SPRYCEL 20 mg filmom obložene tablete SPRYCEL 50 mg filmom obložene tablete SPRYCEL 70 mg filmom obložene tablete SPRYCEL 80 mg filmom obložene tablete SPRYCEL 100 mg filmom obložene tablete SPRYCEL 140 mg filmom obložene tablete
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets dasatinib
SPRYCEL 20 mg filmom obložene tablete SPRYCEL 50 mg filmom obložene tablete SPRYCEL 70 mg filmom obložene tablete SPRYCEL 80 mg filmom obložene tablete SPRYCEL 100 mg filmom obložene tablete SPRYCEL 140 mg filmom obložene tablete dasatinib
SPRYCEL 20 mg, 50 mg, 70 mg film-coated tablets
SPRYCEL 20 mg, 50 mg i 70 mg filmom obložene tablete
SPRYCEL 20 mg: the film-coated tablet is white to off-white, biconvex, round with “BMS” debossed on one side and “527” on the other side.
SPRYCEL 20 mg: filmom obložena tableta bijele do gotovo bijele boje, bikonveksna, okrugla, s oznakom “BMS” utisnutom s jedne i oznakom “527” s druge strane.
SPRYCEL 80 mg film-coated tablets dasatinib
SPRYCEL 80 mg filmom obložene tablete dasatinib
SPRYCEL 80 mg tablets dasatinib
SPRYCEL 80 mg tablete dasatinib
SPRYCEL 80 mg, 100 mg, 140 mg film-coated tablets Alu/Alu blisters (perforated unit dose blisters).
SPRYCEL 80 mg, 100 mg i 140 mg filmom obložene tablete Alu/Alu blisteri (perforirani blisteri djeljivi na jedinične doze).
SPRYCEL inhibits the growth of these leukaemic cells.
SPRYCEL sprječava umnažanje tih leukemijskih stanica.
Sprycel is a medicine that contains the active substance dasatinib.
Sprycel je lijek koji sadrži djelatnu tvar dasatinib.
SPRYCEL is also used to treat Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL), and lymphoid blast CML in adults who are not benefiting from prior therapies.
SPRYCEL se koristi i za liječenje akutne limfoblastične leukemije (ALL) s pozitivnim Philadelphia kromosomom (Ph+) i limfoidne blastne KML u odraslih u kojih prethodno liječenje nije dovelo do poboljšanja.
Sprycel is an anticancer medicine.
Sprycel je antikancerogeni lijek.
SPRYCEL is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.
SPRYCEL je indiciran u liječenju odraslih bolesnika kod: novodijagnosticirane kronične mijeloične leukemije (KML) s pozitivnim Philadelphia kromosomom (Ph+) u kroničnoj fazi. kronične faze, faze ubrzanja ili faze blastne krize KML uz nepodnošenje ili otpornost na prethodnu terapiju, uključujući imatinib mesilat.
SPRYCEL is not recommended for patients below 18 years of age.
SPRYCEL se ne preporučuje u bolesnika mlađih od 18 godina.
SPRYCEL is prescribed for adults.
SPRYCEL se propisuje odraslim osobama.
Sprycel is taken once a day, consistently either in the morning or in the evening.
Sprycel se uzima jednom na dan, kontinuirano ujutro ili uvečer.
Sprycel is used when patients cannot tolerate, or when their disease is not responding to, other treatments.
Sprycel se koristi u bolesnika koji ne podnose ili njihova bolest ne odgovara na druge terapije.
Sprycel tablets must be swallowed whole.
Sprycel tablete treba progutati cijele.
SPRYCEL with food and drink
SPRYCEL s hranom i pićem
Sputum discoloured
Promjena boje ispljuvka
Sputum discoloured Bronchitis Bronchopneumonia Lung infection Pharyngitis
Opstruktivni poremećaj dišnih putova Kongestija dišnih puteva Promjena boje sputuma Bronhitis Bronhopneumonija Infekcija pluća Faringitis
Sputum infection
Infekcija iskašljaja
Squalane Poloxamer 401
Skvalan Poloksamer 401
Squalene 9.75 milligrams
Skvalen 9,75 miligrama
Squalene 9.75 milligrams per 0.5 ml
kvalen 9,75 miligrama na 0,5 ml
Squamous cell (N=473)
kvamoznih
Squamous cell (N=473)
velikih stanica
squamous cell carcinoma
karcinom skvamoznih stanica
Squamous cell carcinoma (SCC) was reported in 1.3% (2/160) of patients treated with Imiquimod, in 0.6% (1/159) treated with vehicle.
Karcinom skvamoznih stanica je prijavljen u 1,3 % (2/160) bolesnika liječenih imikvimodom te u 0,6 % (1/159) bolesnika koji su primali podlogu.
Squamous cell carcinoma of skin
planocelularni karcinom kože
squamous cell carcinoma of skin, basal cell carcinoma, skin papilloma
karcinom skvamoznih stanica kože, karcinom bazalnih stanica, kožni papilomi
Squamous cell carcinoma of the skin (SCC) has been reported in patients , some of whom have reported prior phototoxic reactions.
Karcinom skvamoznih stanica kože (SCC, engl. squamous cell carcinoma) prijavljen je u bolesnika od kojih su neki prethodno prijavili fototoksične reakcije.
Squamous cell carcinoma of the skin (SCC) has been reported in patients, some of whom have reported prior phototoxic reactions.
Karcinom skvamoznih stanica kože (SCC, engl. squamos cell carcinoma) prijavljen je u bolesnika s fototoksičnošću i dodatnim faktorima rizika, uključujući imunosupresiju.
Squamous cell carcinoma of the skin (SCC) has been reported in patients, some of whom have reported prior phototoxic reactions.
Karcinom skvamoznih stanica kože (SCC, engl. squamous cell carcinoma) prijavljen je u bolesnika od kojih su neki prethodno prijavili fototoksične reakcije.
squamous cell carcinoma*
karcinom skvamoznih stanica
squamous NSCLC harbouring EGFR activating mutations, the MAH should
oboljelih od neskvamoznog NSCLC-a s aktivirajućim mutacijama EGFR-a, nositelj
Squamous skin cancer was reported in clinical trials in previously treated myeloma patients with lenalidomide/dexamethasone compared to controls
Rak pločastih stanica kože zabilježen je u kliničkim ispitivanjima bolesnika s prethodno liječenim mijelomom koji su primali lenalidomid/deksametazon u usporedbi s kontrolnom skupinom.
Squeeze all of the contents of one ampoule into the medicine reservoir of the Zirela Nebuliser Handset (Figure 1).
Istisnite sadržaj jedne ampule u spremnik naprave za inhalaciju Zirela Nebuliser Handset (slika 1).
Squeeze and hold at tabs above and below ()
Stisnite i držite za jezičke iznad i ispod ()
Squeeze out the contents completely into the vial (Figure 1d).
Istisnite cijeli sadržaj u bočicu (Slika 1d).
Squeeze pipette firmly applying the entire contents directly to the skin.
Stisnite čvrsto pipetu i primijenite ukupan sadržaj izravno na kožu.
Squeeze pipette, apply about half of the contents half way down the neck between the base of the skull and the shoulder blades.
Stisnite pipetu i nanesite oko polovine sadržaja na vrat između zatiljka i lopatica.
Squeeze the entire contents of the sachet onto your hand (palm or fingertips) or squeeze directly onto the application site. (See Figure D).
Istisnite cijeli sadržaj vrećice na ruku (dlan ili vrhove prstiju) ili ga neposredno istisnite na mjesto primjene. (Pogledajte sliku D).
Squeeze the gel from one tube onto a fingertip.
Istisnite gel iz jedne tube na vrh prsta.
Squeeze the liquid gently into the side of the child’s mouth - towards the inside of their cheek.
Istisnite tekućinu lagano u djetetova usta – prema unutarnjoj strani obraza.
Squeeze the skin at your injection site to make a raised area and hold it firmly.
Uhvatite nabor kože na mjestu ubrizgavanja kako biste dobili izbočinu i čvrsto držite.
SQV Naive/Experienced Population
Prethodno neliječeni/liječeni sakvinavirom
SRD is a measure for sustained disability improvement.
SRD je mjera za trajno poboljšanje onesposobljenosti.
SRE relative risk
Relativni rizik SRE
SRE relative risk
Relativni rizik za SRE
SRH antibody response against an homologous H5N1 Vietnam strain at day 43 reached all CHMP criteria for all 3 strains.
Odgovor antitijela izmjeren jednosmjernom radijalnom hemolizom (engl. single radial haemolysis, SRH) na homologni soj virusa H5N1 Vietnam u 43. danu dosegnuo je sve CHMP-ove kriterije za sva 3 soja.
SRH area > 25 mm²
SRH površina > 25 mm²
SRH area > 25 mm²; MN titer ≥ 1:40;
Površina SRH > 25 mm²; MN titar ≥ 1:40;
SRH area > 25 mm²; MN titer ≥1:40;
Površina SRH > 25 mm²; MN titar ≥ 1:40;
SRH area > 25 mm²; MN titre ≥ 1:40;
Površina SRH > 25 mm²; MN titar ≥ 1:40;
SRH area ≥ 25 mm2
SRH površina  25 mm²
SRH area ≥ 25 mm²
SRH površina  25 mm²
SRH Assay
SRH analiza
SRH Assay All subjects Seronegative subjects at baseline (≤ 4mm2)
SRH analiza Svi ispitanici Ispitanici seronegativni na početku (≤ 4mm2)
SRH results after the first dose, that mimic prepandemic priming plus single heterologous booster dose, met all CHMP criteria.
SRH rezultati nakon prve doze, koji oponašaju prepandemijsko primarno cijepljenje, povrh još jedne heterologne booster doze, zadovoljili su sve CHMP-ove kriterije.
SRI response rate (excluding complement and anti-dsDNA changes) at week 52 (%)
komplementa i anti-dsDNK) u 52. tjednu (%)
SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram.
SSRI (selektivni inhibitori ponovne pohrane serotonina), koji se koriste za liječenje depresije i/ili tjeskobe, uključujući fluoksetin, paroksetin, sertralin, fluvoksamin, citalopram, escitalopram,
SSRIs and SNRIs increased the risk of bleeding in RE-LY in all treatment groups.
SSRI-i i SNRI-i su povećali rizik od krvarenja u ispitivanju RE-LY u svim liječenim skupinama.
SSRIs and SNRIs increased the risk of bleeding in RE-LY in all treatment groups.
SSRI-i i SNRI-i su povećali rizik od krvarenja u ispitivanju RELY u svim liječenim skupinama.
SSRIs and SNRIs)
SSRI i SNRI)
SSRIs and SNRIs): there have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic drugs (including SSRIs and SNRIs).
SSRI i SNRI): prijavljeni su slučajevi serotoninskog sindroma nakon istovremene primjene 5-HT3 antagonista i drugih serotonergičkih lijekova (uključujući SSRI i SNRI).
SSRIs or SNRIs
SSRI ili SNRI
ST elevation, ST depression or left bundle-branch block).
(primjerice ST elevacija, ST depresija ili blok lijeve grane snopa).
ST elevation, ST depression or left bundle-branch block).
depresija ili blok lijeve grane).
St John's Wort
Gospina trava
St John's wort (a herbal preparation used to treat depression).
gospinu travu (biljni pripravak koji se koristi za liječenje depresije).